Ambulatory Transradial Percutaneous Coronary Intervention

Original title: Ambulatory Transradial Percutaneous Coronary Intervention: A Safe, Effective, and Cost-Saving Strategy. Reference: Philippe Le Corvoisier et al. Catheterization and Cardiovascular Interventions 81:15–23 (2013).

The number of PCI procedures has increased and for many interventional cardiology centers PC interventions entail significant resource consumption. Reducing post procedure hospital stay could reduce costs and optimize hospitalization resources. 

The safety of post PCI discharge the same day of procedure should be established before incorporation to daily practice. The aim of this prospective multicenter study was to determine the safety, cost and acceptance of patients undergoing ambulatory transradial PCI. The study took place in 3 high volume centers in France; it assessed 370 consecutive patients with stable angina or silent ischemia for coronary catheterization followed by PCI and same day discharge. From 370 patients, 220 were selected for 4-6 hr observation and discharge. 

Inclusion criteria were:

•+18 years

•Stable angina or silent ischemia

Exclusion criteria: 

•Clinical criteria

ACS, Symptomatic cardiac insufficiency and/or <35% ejection fraction, Severe chronic kidney disease (creatinine clearance

•Social criteria

Doubts on patient acceptance, Place of residence farther than 1 hour from hospital, Inadequate home care.

•PCI related criteria

Approach other than radial, Use of Glycoprotein IIb/IIIa inhibitors, < 3 post interventional TIMI flow , > 1 mm branch occlusion, Persistent chest pain, Hemodynamic instability during procedure, Ventricular arrhythmia during procedure, Procedure completed after 2 pm.

From the 220 patients, 213 (96.8%) were discharged after a 4-6 hr observation period. 4 patients remained hospitalized (1.8%) for cardiovascular reasons and 3 patients (1.4%) for non cardiovascular reasons. At one month follow up, one patient presented a non fatal infarction at day 4 for stent thrombosis and 3 patients were readmitted for atypical chest pain, without ECG changes or troponin elevation. 87% of patients were satisfied with ambulatory management and 96% were open to repeat the experience.

Conclusion 

Ambulatory PCI in stable patients is safe, feasible and well accepted by patients. It’s a promising strategy to lower costs and optimize healthcare resources.

Editorial Comment:

As an observational study, it fails to identify prediction factors; however, the study provides evidence in support of ambulatory PCI as daily practice: it included a significant number of patients with multiple vessels, bifurcations and recanalizations, due to the fact that all PCI procedures were ad hoc, which has external value and easily proves feasibility. Perhaps we could start including the least complex procedures and gain experience to include all procedures, as the present study did.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...